[
    {
        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_10763",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_10763"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB00388"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension, or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [  4.1 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [  4.2 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients  [See  Dosage and Administration section\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB00388",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "CeVfrWlunG5MuE0AHRsdOCenuiibn2U8HgL48VA+FKnlAeC0uC9xqskTjEhrPwaRlnTRgF201nRV6oMPOW1rI15fJgbIFC7bT98K2ngbhUqwx6ebjQ+FE6T7pYjXBSRh7lyBkRCuD8pADJKt7M/mD9cPEa6WC7iBC2XPRCOwuAw="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-25T13:33:11.099+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    }
]